Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingxin Mingmu Shangqing Wan is a traditional Chinese medicine (TCM) developed and manufactured by Guiyang Dechangxiang Pharmaceutical. It is formulated as a pill (Wan) and is primarily indicated for clearing internal heat, detoxifying the body, and improving vision. In TCM theory, it is used to treat upper burner fire syndrome (上焦火盛), which manifests as symptoms such as red, swollen, and painful eyes, photophobia, mouth and tongue ulcers, gum swelling, toothache, and constipation. The formulation typically includes a combination of herbal ingredients known for their cooling and anti-inflammatory properties, such as Coptis chinensis, Scutellaria baicalensis, and Rheum palmatum. It is an approved and marketed product in China, often used as an over-the-counter remedy for acute inflammatory conditions of the head and face.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingxin Mingmu Shangqing Wan.